The stock's rise snapped a four-day losing streak.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and ...

Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals by 28.1% in Q4, selling 115,479 shares. The fund now owns ...

The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

In a first week meant to overwhelm the cognitive capabilities of critics, the media and the average citizen, President Donald Trump upended policies and norms across the federal government. Join ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...